{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T07:31:21Z","timestamp":1774510281874,"version":"3.50.1"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Of the various medical therapies for heart failure (HF), sacubitril\/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor that combines sacubitril, a pro-drug that is further metabolized to the neprilysin inhibitor sacubitrilat, and the angiotensin II type 1 receptor blocker valsartan. Inhibition of neprilysin and blockade of the angiotensin II type 1 receptor with sacubitril\/valsartan increases vasoactive peptide levels, increasing vasodilation, natriuresis, and diuresis. Left ventricular ejection fraction (LVEF) is widely used to classify HF, to assist with clinical decision-making, for patient selection in HF clinical trials, and to optimize the benefits of sacubitril\/valsartan in HF. However, as HF is a complex syndrome that occurs on a continuum of overlapping and changing phenotypes, patient classification based solely on LVEF becomes problematic. LVEF measurement can be imprecise, have low reproducibility, and often changes over time. LVEF may not accurately reflect inherent disease heterogeneity and complexity, and the addition of alternate criteria to LVEF may improve phenotyping of HF and help guide treatment choices. Sacubitril\/valsartan may work, in part, by mechanisms that are not directly related to the LVEF. For example, this drug may exert antifibrotic and neurohumoral modulatory effects through inhibition or activation of several signaling pathways. In this review, we discuss markers of cardiac remodeling, fibrosis, systemic inflammation; activation of neurohormonal pathways, including the natriuretic system and the sympathetic nervous system; the presence of comorbidities; patient characteristics; hemodynamics; and HF signs and symptoms that may all be used to (1) better understand the mechanisms of action of sacubitril\/valsartan and (2) help to identify subsets of patients who might benefit from treatment, regardless of LVEF.<\/jats:p>","DOI":"10.3389\/fcvm.2022.1058998","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T15:28:45Z","timestamp":1671722925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril\/valsartan in heart failure"],"prefix":"10.3389","volume":"9","author":[{"given":"Sheldon E.","family":"Litwin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara A.","family":"East","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jacc.2020.06.016","article-title":"Sacubitril\/valsartan as antifibrotic drug: rejuvenating the fibrosed HFpEF heart.","volume":"76","author":"Bayes-Genis","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.ihj.2018.01.002","article-title":"Sacubitril\/valsartan: a novel angiotensin receptor-neprilysin inhibitor.","volume":"70","author":"Dargad","year":"2018","journal-title":"Indian Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.","volume":"34","author":"Mangiafico","year":"2013","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.","volume":"130","author":"Volpe","year":"2016","journal-title":"Clin Sci (Lond)."},{"key":"B5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10741-017-9605-8","article-title":"Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF.","volume":"22","author":"Rubattu","year":"2017","journal-title":"Heart Fail Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging.","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1161\/CIRCULATIONAHA.120.045008","article-title":"Substance and substrate: LVEF and sex subgroup analyses of PARAGON-HF and PARADIGM-HF trials.","volume":"141","author":"Bozkurt","year":"2020","journal-title":"Circulation."},{"key":"B8","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J."},{"key":"B10","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation\/American heart association task force on practice guidelines.","volume":"128","author":"Writing Committee","year":"2013","journal-title":"Circulation."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-020-01349-3","article-title":"Heart failure with preserved ejection fraction-a concise review.","volume":"22","author":"Adamczak","year":"2020","journal-title":"Curr Cardiol Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.ddstr.2013.11.002","article-title":"Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure.","volume":"9","author":"Langenickel","year":"2012","journal-title":"Drug Discov Today Ther Strateg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40256-017-0219-2","article-title":"Management of heart failure with preserved ejection fraction: current challenges and future directions.","volume":"17","author":"Upadhya","year":"2017","journal-title":"Am J Cardiovasc Drugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective.","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/heartjnl-2020-317604","article-title":"What is \u2018normal\u2019 left ventricular ejection fraction?","volume":"106","author":"Hudson","year":"2020","journal-title":"Heart."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.jacc.2020.09.012","article-title":"Time to reframe ejection fraction in light of new pathophysiological insights into heart failure.","volume":"76","author":"Liu","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001073","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation."},{"key":"B18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","article-title":"SGLT2 inhibitors and their mode of action in heart failure-has the mystery been unravelled?","volume":"18","author":"Pabel","year":"2021","journal-title":"Curr Heart Fail Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure.","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1093\/eurheartj\/ehaa184","article-title":"A putative placebo analysis of the effects of sacubitril\/valsartan in heart failure across the full range of ejection fraction.","volume":"41","author":"Vaduganathan","year":"2020","journal-title":"Eur Heart J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijcard.2022.01.004","article-title":"Benefit from sacubitril\/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: an echocardiographic study.","volume":"350","author":"Carluccio","year":"2022","journal-title":"Int J Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/ehf2.13779","article-title":"Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril\/valsartan.","volume":"9","author":"Dini","year":"2022","journal-title":"ESC Heart Fail."},{"key":"B23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcmg.2015.02.014","article-title":"Ethnic-specific normative reference values for echocardiographic LA and LV Size, LV mass, and systolic function: the EchoNoRMAL study.","volume":"8","year":"2015","journal-title":"JACC Cardiovasc Imaging."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.echo.2019.07.019","article-title":"Feasibility and reproducibility of transthoracic echocardiography in obese patients.","volume":"32","author":"Snelder","year":"2019","journal-title":"J Am Soc Echocardiogr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"Cardiac remodeling\u2014concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling.","volume":"35","author":"Cohn","year":"2000","journal-title":"J Am Coll Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1161\/CIRCRESAHA.114.302819","article-title":"Dynamic changes in myocardial matrix and relevance to disease: translational perspectives.","volume":"114","author":"Li","year":"2014","journal-title":"Circ Res."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010242","article-title":"Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding.","volume":"9","author":"Simmonds","year":"2020","journal-title":"Cells."},{"key":"B28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach.","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in n-terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction.","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction.","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis.","volume":"8","author":"Wang","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction.","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","article-title":"Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness.","volume":"72","author":"Jia","year":"2018","journal-title":"Hypertension."},{"key":"B34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.","volume":"8","author":"von Lueder","year":"2015","journal-title":"Circ Heart Fail."},{"key":"B35","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jchf.2019.06.004","article-title":"Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction.","volume":"7","author":"Aimo","year":"2019","journal-title":"JACC Heart Fail."},{"key":"B36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jchf.2020.09.013","article-title":"Atrial natriuretic peptide and treatment with sacubitril\/valsartan in heart failure with reduced ejection fraction.","volume":"9","author":"Murphy","year":"2021","journal-title":"JACC Heart Fail."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","article-title":"Prognostic implications of changes in N-terminal Pro-B-type natriuretic peptide in patients with heart failure.","volume":"68","author":"Zile","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","article-title":"Effect of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF.","volume":"76","author":"Cunningham","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-Neprilysin inhibition in acute decompensated heart failure.","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the parallax randomized clinical trial.","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA."},{"key":"B41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","article-title":"Effects of sacubitril\/valsartan on N-terminal Pro-B-type natriuretic peptide in heart failure with preserved ejection fraction.","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC Heart Fail."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112629","article-title":"Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications.","volume":"20","author":"Tanase","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/joim.12756","article-title":"Biomarkers for heart failure: small molecules with high clinical relevance.","volume":"283","author":"Magnussen","year":"2018","journal-title":"J Intern Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijcard.2017.01.130","article-title":"BNP and obesity in acute decompensated heart failure with preserved vs. Reduced ejection fraction: the atherosclerosis risk in communities surveillance study.","volume":"233","author":"Khalid","year":"2017","journal-title":"Int J Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jacc.2018.02.021","article-title":"Myocardial interstitial fibrosis in heart failure: biological and translational perspectives.","volume":"71","author":"Gonzalez","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrcardio.2012.158","article-title":"Myofibroblast-mediated mechanisms of pathological remodelling of the heart.","volume":"10","author":"Weber","year":"2013","journal-title":"Nat Rev Cardiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/CIRCHEARTFAILURE.109.931451","article-title":"Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction.","volume":"4","author":"Westermann","year":"2011","journal-title":"Circ Heart Fail."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1093\/eurheartj\/ehz240","article-title":"Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.","volume":"40","author":"Morrow","year":"2019","journal-title":"Eur Heart J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jchf.2017.04.007","article-title":"Biomarker profiles of acute heart failure patients with a mid-range ejection fraction.","volume":"5","author":"Tromp","year":"2017","journal-title":"JACC Heart Fail."},{"key":"B50","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.hfc.2020.06.005","article-title":"Addressing comorbidities in heart failure: hypertension, atrial fibrillation, and diabetes.","volume":"16","author":"Bavishi","year":"2020","journal-title":"Heart Fail Clin."},{"key":"B51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/164_2017_27","article-title":"Comorbidities in heart failure.","volume":"243","author":"van der Wal","year":"2017","journal-title":"Handb Exp Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ejhf.250","article-title":"Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.","volume":"17","author":"McMurray","year":"2015","journal-title":"Eur J Heart Fail."},{"key":"B53","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.cardfail.2020.04.011","article-title":"Sacubitril\/valsartan improves left ventricular function in chronic pressure overload independent of intact cyclic guanosine monophosphate-dependent protein kinase I alpha signaling.","volume":"26","author":"Tam","year":"2020","journal-title":"J Card Fail."},{"key":"B54","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jacc.2013.11.031","article-title":"Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data.","volume":"63","author":"Damman","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure.","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction.","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation."},{"key":"B57","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med."},{"key":"B58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial.","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the paradigm-HF trial.","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cpcardiol.2014.09.002","article-title":"Concomitant diabetes mellitus and heart failure.","volume":"40","author":"Dei Cas","year":"2015","journal-title":"Curr Probl Cardiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","article-title":"Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.","volume":"3","author":"Dei Cas","year":"2015","journal-title":"JACC Heart Fail."},{"key":"B62","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.amjmed.2006.05.024","article-title":"Diabetes in heart failure: prevalence and impact on outcome in the population.","volume":"119","author":"From","year":"2006","journal-title":"Am J Med."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004646","article-title":"Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the get with the guidelines-heart failure registry.","volume":"11","author":"Sharma","year":"2018","journal-title":"Circ Heart Fail."},{"key":"B64","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jchf.2020.09.014","article-title":"Reverse cardiac remodeling following initiation of sacubitril\/valsartan in patients with heart failure with and without diabetes.","volume":"9","author":"Khan","year":"2021","journal-title":"JACC Heart Fail."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial.","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail."},{"key":"B67","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF.","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/ejhf.2005","article-title":"Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan.","volume":"22","author":"Ibrahim","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007829","article-title":"Racial and ethnic differences in biomarkers, health status, and cardiac remodeling in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan.","volume":"13","author":"Ibrahim","year":"2020","journal-title":"Circ Heart Fail."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.","volume":"41","author":"Shekelle","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jchf.2020.06.019","article-title":"Angiotensin-neprilysin inhibition in black Americans: data from the PIONEER-HF trial.","volume":"8","author":"Berardi","year":"2020","journal-title":"JACC Heart Fail."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1058998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T15:28:51Z","timestamp":1671722931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1058998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":72,"alternative-id":["10.3389\/fcvm.2022.1058998"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1058998","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"article-number":"1058998"}}